Rating Rationale
March 31, 2022 | Mumbai
Bioxera Pharma Private Limited
Rating outlook revised to 'Positive'; Ratings Reaffirmed
 
Rating Action
Total Bank Loan Facilities RatedRs.19 Crore
Long Term RatingCRISIL BB+/Positive (Outlook revised from 'Stable'; Rating Reaffirmed)
Short Term RatingCRISIL A4+ (Reaffirmed)
1 crore = 10 million
Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

CRISIL Ratings has revised its outlook on the bank facilities of Bioxera Pharma Private Limited (BPPL) to ‘Positive’ from ‘Stable’ while reaffirming its long term rating at CRISIL BB+. The rating on the short-term facilities has been reaffirmed at ‘CRISIL A4+.

 

The revision in outlook reflects expected sustained improvement in business risk profile over the medium term, supported by improved volumes as well as realizations. Company is expected to report revenue upwards of Rs 70 crore in fiscal 2022 with operating margin expected to sustain at improved levels of fiscal 2021 (around 25%). Further, capacity expansion in fiscal 2022 is expected to support volume growth over medium term. Consequently, financial risk profile especially debt protection metrics is expected to improve. Sustenance of growth while maintaining operating margin to remain rating sensitivity factor.

 

The ratings continue to reflect the established customer & supplier relationship on the back extensive experience of the promoters in the pharmaceutical industry and comfortable financial risk profile. These strengths are partially offset by susceptibility to fluctuations in raw material prices and moderate scale of operations amid intense competition.

Analytical Approach

Unsecured loan of Rs 5.44 crore as on March 31, 2021, from the promoters has been treated as debt as it is not expected to remain in the business over medium term.

Key Rating Drivers & Detailed Description

Strengths:

  • Established customer & supplier relationship on the back of extensive industry experience of the promoters: The promoters' educational qualification, and over three decades of experience in the pharmaceutical industry, has helped developed sound understanding of market dynamics and healthy relationships with suppliers and customers. The company has steadily added new products, and have customers like Bremen Trading Dwc LLC, Reckitt Benckiser for more than 5 years.

 

  • Comfortable financial risk profile: Total outside liabilities to adjusted networth of 0.83 times on a networth base of Rs. 20.26 crores as on March 31, 2021 represents healthy capital structure. Debt protection metrics were comfortable, with interest coverage and net cash accrual to adjusted debt ratios of 9.18 times and ~0.53 time, respectively in fiscal 2021. The financial risk profile will remain comfortable over the medium term supported healthy accretion of profit to reserves.

 

Weaknesses:

  • Susceptibility to fluctuations in raw material prices: Profitability is susceptible to volatility in raw material prices as it contributes ~50-60 % of the cost. However, the company had benefited from decline in raw material cost in FY21, resulting in improved margins for fiscal 2021 of ~25.5%. In fiscal 2022 also, the company is expected to register EBIDTA margin of more than ~25% on account of lower raw material prices along with improved realizations and volumes. However, in case of rise in input prices of raw materials, the company will not be able to pass on the price rise to customers, making the profitability susceptible to input cost.

 

  • Moderate scale of operations amidst intense competition: The Company’s turnover is expected to be more than ~Rs. 70 crores in fiscal 2022 improving from ~Rs. 49 crores in fiscal 2021. However, the scale remains moderate in the intensely competitive bulk drug manufacturing industry. Moderate scale of operations restrains company’s bargaining power with customers and suppliers.

Liquidity: Adequate

Company has adequate liquidity driven by expected cash accruals of more than Rs. 13 crore against repayment obligations of ~Rs. 1.5-1.6 crores over medium term. Company had cash and cash equivalents (unencumbered) of ~Rs. 4.5 crore as on March 31, 2021 & fund based utilization remains low at an average of ~10% over past 12 months. No major capex is expected over medium term. Current ratio was at 1.31 times as on March 31, 2021. CRISIL Ratings believes the company has sufficient accruals and cash and cash equivalents to meet incremental working capital needs over the next one year

Outlook: Positive

CRISIL Ratings believes BPPL will continue to benefit over the medium term from its promoters' extensive industry experience.

Rating Sensitivity factors

Upward factors

  • Growth in revenue by ~30% along with sustenance of operating margins above ~20%.
  • Sustenance of financial risk profile

 

Downward factors

  • Decline in revenue leading to operating margins below 15%
  • Deterioration in capital structure caused by more than expected debt funded capital expenditure or further stretch in working capital cycle.

About the Company

Incorporated in 2005 by Mr Ajit Gunjkar, Mr Santosh Gunjkar and Ms Sudha Gunjkar, BPPL manufactures bulk drugs for the domestic and global markets. The main products include Benfotiamine, Amylmetacresol, and 2, 4-Dichlorobenzyl alcohol. The manufacturing facility is in Ambernath, Maharashtra.

Key Financial Indicators

Particulars

Unit

2021 (Act.)

2020 (Act.)

Revenue

Rs. Crore

55.8

53.1

Profit After Tax (PAT)

Rs. Crore

7.9

2.8

PAT Margin

%

14.1

5.2

Adjusted debt/adjusted networth

Times

0.8

1.1

Interest coverage

Times

9.2

4.3

 

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL Ratings' complexity levels are assigned to various types of financial instruments. The CRISIL Ratings' complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL Ratings' complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN

Name of instrument

Date of

allotment

Coupon
rate (%)

Maturity date

Issue size
(Rs. Crore)

Complexity
levels

Rating assigned

with outlook

NA

Bank Guarantee

NA

NA

NA

0.6

NA

CRISIL A4+

NA

Cash Credit

NA

NA

NA

4

NA

CRISIL BB+/Positive

NA

Corporate Loan

NA

NA

31-Mar-24

2.84

NA

CRISIL BB+/Positive

NA

Letter of Credit

NA

NA

NA

3.5

NA

CRISIL A4+

NA

Proposed Long Term Bank Loan Facility

NA

NA

NA

0.59

NA

CRISIL BB+/Positive

NA

Term Loan

NA

NA

Dec-26

7.47

NA

CRISIL BB+/Positive

 

Annexure - Rating History for last 3 Years
  Current 2022 (History) 2021  2020  2019  Start of 2019
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund Based Facilities LT 14.9 CRISIL BB+/Positive   --   -- 10-12-20 CRISIL BB+/Stable 26-11-19 CRISIL BB+/Stable CRISIL BB+/Stable
      --   --   --   -- 05-03-19 CRISIL BB+/Stable CRISIL BB/Stable
Non-Fund Based Facilities ST 4.1 CRISIL A4+   --   -- 10-12-20 CRISIL A4+ 26-11-19 CRISIL A4+ CRISIL A4+
      --   --   --   -- 05-03-19 CRISIL A4+ --
All amounts are in Rs.Cr.
Annexure - Details of Bank Lenders & Facilities
Facility Amount (Rs.Crore) Name of Lender Rating
Bank Guarantee 0.6 Saraswat Bank CRISIL A4+
Cash Credit 4 Saraswat Bank CRISIL BB+/Positive
Corporate Loan 0.32 Saraswat Bank CRISIL BB+/Positive
Corporate Loan 2.52 Saraswat Bank CRISIL BB+/Positive
Letter of Credit 3.5 Saraswat Bank CRISIL A4+
Proposed Long Term Bank Loan Facility 0.59 Not Applicable CRISIL BB+/Positive
Term Loan 0.47 Saraswat Bank CRISIL BB+/Positive
Term Loan 3.65 Saraswat Bank CRISIL BB+/Positive
Term Loan 3 Saraswat Bank CRISIL BB+/Positive
Term Loan 0.35 Saraswat Bank CRISIL BB+/Positive

This Annexure has been updated on 31-Mar-22 in line with the lender-wise facility details as on 18-Aug-21 received from the rated entity.

Criteria Details
Links to related criteria
CRISILs Approach to Financial Ratios
Rating criteria for manufaturing and service sector companies
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating Criteria for the Pharmaceutical Industry
Understanding CRISILs Ratings and Rating Scales

Media Relations
Analytical Contacts
Customer Service Helpdesk

Pankaj Rawat
Media Relations
CRISIL Limited
B: +91 22 3342 3000
pankaj.rawat@crisil.com

Hiral Jani Vasani
Media Relations
CRISIL Limited
B: +91 22 3342 3000
hiral.vasani@crisil.com

Rutuja Gaikwad 
Media Relations
CRISIL Limited
B: +91 22 3342 3000
Rutuja.Gaikwad@ext-crisil.com


Rahul Subrato Kumar Guha
Director
CRISIL Ratings Limited
D:+91 22 4097 8320
rahul.guha@crisil.com


Jumana Badshah
Associate Director
CRISIL Ratings Limited
D:+91 22 3342 8324
Jumana.Badshah@crisil.com


Raj Kumar Inani
Senior Rating Analyst
CRISIL Ratings Limited
B:+91 22 3342 3000
Raj.Inani@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL Ratings. However, CRISIL Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.


About CRISIL Ratings Limited (A subsidiary of CRISIL Limited)

CRISIL Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).
 
CRISIL Ratings Limited ('CRISIL Ratings') is a wholly-owned subsidiary of CRISIL Limited ('CRISIL'). CRISIL Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").
 
For more information, visit www.crisilratings.com 

 



About CRISIL Limited

CRISIL is a global analytical company providing ratings, research, and risk and policy advisory services. We are India's leading ratings agency. We are also the foremost provider of high-end research to the world's largest banks and leading corporations.

CRISIL is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.


For more information, visit www.crisil.com

Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK


CRISIL PRIVACY NOTICE
 
CRISIL respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from CRISIL. For further information on CRISIL’s privacy policy please visit www.crisil.com.



DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale (‘report’) that is provided by CRISIL Ratings Limited (‘CRISIL Ratings’). To avoid doubt, the term ‘report’ includes the information, ratings and other content forming part of the report. The report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRISIL Ratings providing or intending to provide any services in jurisdictions where CRISIL Ratings does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this report does not create a client relationship between CRISIL Ratings and the user.

We are not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing our report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Ratings are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL Ratings assumes no obligation to update its opinions following publication in any form or format although CRISIL Ratings may disseminate its opinions and analysis. The rating contained in the report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way. CRISIL Ratings or its associates may have other commercial transactions with the entity to which the report pertains.

Neither CRISIL Ratings nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively, ‘CRISIL Ratings Parties’) guarantee the accuracy, completeness or adequacy of the report, and no CRISIL Ratings Party shall have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. EACH CRISIL RATINGS PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Ratings Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. Public ratings and analysis by CRISIL Ratings, as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any), are made available on its website, www.crisilratings.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about ratings by CRISIL Ratings are available here: www.crisilratings.com.

CRISIL Ratings and its affiliates do not act as a fiduciary. While CRISIL Ratings has obtained information from sources it believes to be reliable, CRISIL Ratings does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and/or relies on in its reports. CRISIL Ratings has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For details please refer to:
https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html.

Rating criteria by CRISIL Ratings are generally available without charge to the public on the CRISIL Ratings public website, www.crisilratings.com. For latest rating information on any instrument of any company rated by CRISIL Ratings, you may contact the CRISIL Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 1301.

This report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRISIL Ratings.

All rights reserved @ CRISIL Ratings Limited. CRISIL Ratings is a wholly owned subsidiary of CRISIL Limited.

 

 

CRISIL Ratings uses the prefix ‘PP-MLD’ for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on CRISIL Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: https://www.crisil.com/en/home/our-businesses/ratings/credit-ratings-scale.html